S1077
Clinical – Upper GI
ESTRO 2026
， B. Zheng ， X.He ， Y. Wang ， DL Kaplan ， Y. Li ， G. Li ， X. Wang ， P. Lan ， Adv. Healthcare Mater. 2018 ， 7 ， 1801213.https://doi.org/10.1002/adhm.201801213.[ 2] S. Yao, S. Wang, M. Zheng, Z. Wang, Z. Liu, Z. L. Wang, L. Li, Implantable, Biodegradable, and Wireless Triboelectric Devices for Cancer Therapy through Disrupting Microtubule and Actins Dynamics. Adv. Mater. 2023, 35, 2303962. https://doi.org/10.1002/adma.202303962. Keywords: sophageal carcinoma, Bioresorbable stent Proffered Paper 1852 A prospective randomised trial to evaluate radiological response and surgical down staging after NACRT versus NACT in unresectable gall bladder cancer Shabnum Thakur, Poorva Vias, Bhagat Chand Radiotherapy and Oncology, Dr RPGMC Tanda, Kangra, India Purpose/Objective: Most gallbladder cancers present at an advanced stage, with only 10%–30% being resectable1. For unresectable locally advanced gallbladder cancer (LAGB), gemcitabine–cisplatin chemotherapy is the standard, followed by surgery when feasible. A pilot2 study of 28 patients treated with neoadjuvant chemoradiotherapy (NACRT) achieved 47% R0 resections, though evidence remains limited and inconsistent. As the optimal neoadjuvant strategy is unclear, this study compared NACRT and neoadjuvant chemotherapy (NACT) in unresectable LAGB. The primary aim was to compare radiologic responses; secondary aims includes resectability, treatment- related toxicities, quality of life, and overall survival (OS). Material/Methods: Patients aged 18–75 years with histologically confirmed, unresectable T3/T4 locally advanced gallbladder cancer (LAGB) with ≤ 3 cm liver invasion and regional lymphadenopathy were randomized (computer-generated blocks) to either NACT or NACRT. The NACRT group received external beam radiotherapy (50.4 Gy in 28 fractions over 5 weeks) by IMRT/VMAT, with concurrent gemcitabine (300 mg/m ² weekly), followed by response assessment one-month post-treatment using triple-phase contrast-enhanced CT (CECT). The NACT group received six cycles of gemcitabine (1000 mg/m ² ) and cisplatin (25 mg/m ² ) on days 1 and 8 every 3 weeks, followed by radiologic response evaluation and surgical assessment using triple-phase CECT. Results:
Digital Poster 1801
A therapeutic and fully bioresorbable esophageal stent for on-demand treatment of esophageal carcinoma Qian Han 1 , Jinyi Lang 2 , Meihua Chen 2 1 School of Medicine, University of Electronic Science and Technology of China, Chengdu, China. 2 Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, Chengdu, China Purpose/Objective: Esophageal carcinoma leading to malignant strictures presents a complex therapeutic challenge, where palliation and active treatment are equally critical. Current stents merely provide mechanical support and do not address tumor progression. This study aims to develop a transformative solution: a fully bioresorbable esophageal stent that not only relieves dysphagia but also serves as an implantable therapeutic platform for localized, on-demand treatment of the carcinoma itself. Material/Methods: We engineered a novel stent from a biocompatible and bioresorbable material. This stent was functionally designed to interact with a non-invasive, external ultrasound source. Its mechanical performance was characterized to ensure efficacy in maintaining esophageal patency. The core anti-tumor capability was evaluated in vitro by co-culturing the stent with human esophageal carcinoma cells and applying a targeted ultrasound stimulus. Cell viability was quantitatively analyzed post-treatment. Results: The stent displayed sufficient radial force and flexibility in bench-top testing, suggesting its potential for maintaining lumen patency. Crucially, upon remote activation by external ultrasound, the stent elicited a potent and localized anti-tumor effect. In vitro testing demonstrated a significant 75% reduction in the viability of esophageal carcinoma cells, directly attributable to the ultrasound-triggered therapeutic action of the stent. The device maintained mechanical integrity for a predetermined duration before undergoing controlled bioresorption. Conclusion: We have successfully developed a multifunctional, fully bioresorbable stent that integrates potential mechanical support with on-demand, localized therapy for esophageal carcinoma. This platform represents a paradigm shift from passive palliation to active intervention, offering a promising one-step strategy to manage both the obstruction and the underlying cancer, ultimately eliminating the need for stent retrieval. References: [1] X. Xie ， X. Zheng ， Z. Han ， Y. Chen ， Z. Zheng
Made with FlippingBook - Share PDF online